Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 160 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Fibroids, Uterine Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

NCT04856306
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Fibroid Uterus
Interventions
Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product
Other · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 1, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation

NCT00295217
View directory record Official record
Conditions
Uterine Fibroids, Uterine Leiomyomas
Interventions
ExAblate 2000
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
4
States / cities
La Jolla, California • Burlington, Massachusetts • Kalamazoo, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 1, 2026, 2:59 PM EDT
Recruiting No phase listed Observational

Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids

NCT05386615
View directory record Official record
Conditions
Uterine Fibroid
Interventions
Body System - Functional
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Stanford, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 1, 2026, 2:59 PM EDT
Completed Phase 2 Interventional

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

NCT00044876
View directory record Official record
Conditions
Leiomyoma
Interventions
CDB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
33 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 1, 2026, 2:59 PM EDT
Terminated Phase 4 Interventional Results available

Preemptive Analgesia Following Uterine Artery Embolization

NCT01555073
View directory record Official record
Conditions
Uterine Fibroids, Uterine Artery Embolization
Interventions
pregabalin/celecoxib, pregabalin/placebo, celecoxib/placebo, Placebo group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 1, 2026, 2:59 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE

NCT06705075
View directory record Official record
Conditions
Uterine Fibroid
Interventions
Perfluten
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 1, 2026, 2:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids

NCT00874029
View directory record Official record
Conditions
Uterine Fibroids, Uterine Myomas
Interventions
Halt Procedure
Device
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
25 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 1, 2026, 2:59 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prescription of Letrozole for Uterine Myoma

NCT06143631
View directory record Official record
Conditions
Leiomyoma, Uterine, Leiomyoma, Fibroid, Fibroid Uterus
Interventions
Letrozole 2.5mg, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 53 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 1, 2026, 2:59 PM EDT
Withdrawn Not applicable Interventional

Home Examinations Researching and Understanding Submucosal Evaluations

NCT05004870
View directory record Official record
Conditions
Fertility Issues
Interventions
Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)
Device
Lead sponsor
Turtle Health, Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 1, 2026, 2:59 PM EDT
Completed No phase listed Observational

Risk Factors for Uterine Fibroids: A Case Control Study

NCT00339547
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 1, 2026, 2:59 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies

NCT04311073
View directory record Official record
Conditions
Fibroid Uterus, Abnormal Uterine Bleeding, Myoma;Uterus
Interventions
Tranexamic Acid, Placebos
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 1, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03412890
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
104
States / cities
Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 1, 2026, 2:59 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03070951
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Chino, California • Huntington Park, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 1, 2026, 2:59 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Uterine Artery Embolization and Pelvic Floor Symptoms

NCT00827645
View directory record Official record
Conditions
Leiomyoma, Incontinence, Prolapse
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 1, 2026, 2:59 PM EDT
Terminated Not applicable Interventional Results available

Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding

NCT00496080
View directory record Official record
Conditions
Menorrhagia, Uterine Fibroids
Interventions
Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 1, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

NCT02691494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 1, 2026, 2:59 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

NCT02889848
View directory record Official record
Conditions
Fibroids, Uterine, Leiomyoma
Interventions
Saline, EN3835
Other · Drug
Lead sponsor
Advance Biofactures Corporation
Industry
Eligibility
35 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 1, 2026, 2:59 PM EDT
Terminated Phase 2Phase 3 Interventional

Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids

NCT01504308
View directory record Official record
Conditions
Uterine Fibroids
Interventions
MR-HIFU treatment, Sham treatment
Device
Lead sponsor
Philips Healthcare
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Chicago, Illinois • Ann Arbor, Michigan • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 1, 2026, 2:59 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Intraoperative Ultrasound in Laparoscopic or Robotic Myomectomy Patients

NCT02879058
View directory record Official record
Conditions
Fibroid Uterus, Quality of Life
Interventions
Intraoperative contact ultrasonography
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 1, 2026, 2:59 PM EDT
Completed Not applicable Interventional

MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids

NCT00166270
View directory record Official record
Conditions
Uterine Fibroids
Interventions
ExAblate 2000
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 1, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03886220
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Elagolix, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
45
States / cities
Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 1, 2026, 2:59 PM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma

NCT01553123
View directory record Official record
Conditions
Leiomyomas
Interventions
Ulipristal Acetate, Iron
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 1, 2026, 2:59 PM EDT
Terminated Phase 2 Interventional Results available

Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy

NCT05017246
View directory record Official record
Conditions
Cancer Debulking, Enlarged Uterus, Fibroid Uterus, Adnexal Mass
Interventions
Bupivacaine, Morphine, Lidocaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 1, 2026, 2:59 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

NCT00735553
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 1, 2026, 2:59 PM EDT